Cargando…

Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer

BACKGROUND: There are no definite recommendations on the optimal time of initiating radioactive iodine (RAI) therapy for differentiated thyroid cancer (DTC) patients in current relevant guidelines. This study aimed to investigate the relationship between the timing of initiating radioiodine adjuvant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Feng, Li, Xue, Ji, Yanhui, Tan, Jian, Zhang, Guizhi, Wang, Peng, He, Yajing, Wang, Renfei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630653/ https://www.ncbi.nlm.nih.gov/pubmed/34858329 http://dx.doi.org/10.3389/fendo.2021.743310

Ejemplares similares

Predictive Value of Thyroglobulin Changes for the Curative Effect of Radioiodine Therapy in Patients With Metastatic Differentiated Thyroid Carcinoma
por: Wang, Congcong, et al.
Publicado: (2021)

Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration
por: Sun, Yu-qing, et al.
Publicado: (2022)

Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy
por: Wang, Congcong, et al.
Publicado: (2023)

Retrospective study of the influence of hypothyroidism on liver function before radioiodine therapy in China: a comparison analysis based on patients with differentiated thyroid cancer
por: Ji, Yanhui, et al.
Publicado: (2022)

Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: An 8-year retrospective study
por: Wang, Renfei, et al.
Publicado: (2017)

Adjuvant Radioiodine for Intermediate-Risk Papillary Thyroid Cancer—To Treat or Not to Treat
por: van Velsen, Evert F S, et al.
Publicado: (2023)

Analysis of risk factors of rapid thyroidal radioiodine-131 turnover in Graves’ disease patients
por: Zhang, Ruiguo, et al.
Publicado: (2017)

Distinguishing Patients With Distant Metastatic Differentiated Thyroid Cancer Who Biochemically Benefit From Next Radioiodine Treatment
por: Sa, Ri, et al.
Publicado: (2020)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
por: Tumino, Dario, et al.
Publicado: (2017)

Alterations in Oral Microbiota of Differentiated Thyroid Carcinoma Patients With Xerostomia After Radioiodine Therapy
por: Lin, Baiqiang, et al.
Publicado: (2022)

Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study
por: Chai, Jinyan, et al.
Publicado: (2022)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
por: Hong, Chae Moon, et al.
Publicado: (2017)

A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer
por: Meng, Chao, et al.
Publicado: (2023)

Do radioiodine-avid lymph nodes from differentiated thyroid cancer on the initial posttherapy scan need repeated (131)I therapy?
por: Jiang, Yongji, et al.
Publicado: (2023)

Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?
por: Gomes-Lima, Cristiane J., et al.
Publicado: (2021)

Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult
por: Zhao, Xianlan, et al.
Publicado: (2022)

Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit
por: Wirth, Lori J, et al.
Publicado: (2022)

Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead
por: Satapathy, Swayamjeet, et al.
Publicado: (2022)

Weathering the Storm: Thyroid Storm Precipitated by Radioiodine Contrast in Metastatic Thyroid Carcinoma
por: Basida, Brinda, et al.
Publicado: (2021)

Initial Evaluation of Therapy Response after Adjuvant Radioiodine Therapy in Patients with Early-Stage Papillary Thyroid Cancer—Does Time Matter?
por: Grawe, Freba, et al.
Publicado: (2022)

The association between the interval of radioiodine treatment and treatment response, and side effects in patients with lung metastases from differentiated thyroid cancer
por: Wang, Hongxi, et al.
Publicado: (2023)

Randomized Clinical Trial: Probiotics Alleviated Oral-Gut Microbiota Dysbiosis and Thyroid Hormone Withdrawal-Related Complications in Thyroid Cancer Patients Before Radioiodine Therapy Following Thyroidectomy
por: Lin, Baiqiang, et al.
Publicado: (2022)

Efficacy of radiofrequency ablation for metastatic papillary thyroid cancer with and without initial biochemical complete status
por: Chen, Wen-Chieh, et al.
Publicado: (2022)

Prediction of thyroidal (131)I effective half-life in patients with Graves' disease
por: Zhang, Ruiguo, et al.
Publicado: (2017)

To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients
por: Carballo, Marilee, et al.
Publicado: (2012)

GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy
por: Barros-Filho, Mateus C., et al.
Publicado: (2020)

Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials
por: Auttara-atthakorn, Arunrat, et al.
Publicado: (2022)

Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
por: Huang, Shuhui, et al.
Publicado: (2022)

Re-treatment With Adjuvant Radioactive Iodine Does Not Improve Recurrence-Free Survival of Patients With Differentiated Thyroid Cancer
por: Bouvet, Clément, et al.
Publicado: (2019)

Improved Patient Dosimetry at Radioiodine Therapy by Combining the ICRP Compartment Model and the EANM Pre-Therapeutic Standard Procedure for Benign Thyroid Diseases
por: Andersson, Martin, et al.
Publicado: (2021)

Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study
por: Han, Na, et al.
Publicado: (2023)

Prognostic Impact of Direct (131)I Therapy After Detection of Biochemical Recurrence in Intermediate or High-Risk Differentiated Thyroid Cancer: A Retrospective Cohort Study
por: Carrillo, José F., et al.
Publicado: (2019)

Retinoic acid therapy in patients with radioiodine negative differentiated thyroid cancer and clinical or biochemical evidence of disease: An initial experience
por: Damle, Nishikant, et al.
Publicado: (2011)

Salivary Function after Radioiodine Therapy: Poor Correlation between Symptoms and Salivary Scintigraphy
por: Jonklaas, Jacqueline, et al.
Publicado: (2015)

Effects of first radioiodine ablation on functions of salivary glands in patients with differentiated thyroid cancer
por: Upadhyaya, Arun, et al.
Publicado: (2017)

Radioactive iodine in low- to intermediate-risk papillary thyroid cancer
por: Zhao, Hengqiang, et al.
Publicado: (2022)

Long-Term Outcomes and Prognoses of Elderly Patients (≥65-Years-Old) With Distant Metastases From Well-Differentiated Thyroid Cancer During Radioiodine Therapy and Follow-Up
por: Qiu, Zhong-Ling, et al.
Publicado: (2021)

Case Report: Management of an Elderly Patient With Metastatic Radioiodine-Resistant Differentiated Thyroid Cancer in a Rural Community, Remote From Specialist Oncology Services
por: Wybrew, Rachael, et al.
Publicado: (2021)

Autoimmune/Inflammatory Syndrome Induced by Adjuvants and Thyroid Autoimmunity
por: Watad, Abdulla, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e5rfmgtineddhr6va0tk655dei